Cyclerion - Logo - Blue.png
Cyclerion Updates Corporate Progress
April 10, 2020 07:00 ET | Cyclerion Therapeutics, Inc.
– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –       – Closed enrollment for IW-6463 translational pharmacology...
Cyclerion - Logo - Blue.png
Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
January 13, 2020 07:00 ET | Cyclerion Therapeutics, Inc.
– Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and...
Cyclerion - Logo - Blue.png
Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 27, 2019 07:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
October 30, 2019 07:31 ET | Cyclerion Therapeutics, Inc.
– Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
October 30, 2019 07:30 ET | Cyclerion Therapeutics, Inc.
– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF – – Conference call to be held at 8:30 a.m. ET today – CAMBRIDGE, Mass., Oct. ...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings
October 08, 2019 08:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for...
Cyclerion-WebcastInvite
Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
September 10, 2019 08:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months
August 12, 2019 08:00 ET | Cyclerion Therapeutics, Inc.
– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study of olinciguat in sickle...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
June 11, 2019 08:30 ET | Cyclerion Therapeutics, Inc.
– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases –             – Preclinical data provide insights into...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
June 04, 2019 08:30 ET | Cyclerion Therapeutics, Inc.
– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New...